TrialDiabetes, obesity & metabolism2019

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.

Claire Baker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.